PRECIGEN INC
NASDAQ: PGEN (Precigen, Inc.)
Last update: 7 hours ago8.54
0.33 (4.02%)
| Previous Close | 8.21 |
| Volume | 6,361,552 |
| Price / Earnings (Forward) | 16.89 |
| Price / Sales | 32.22 |
| Price / Book | 61.05 |
| 52 Weeks Range |
| Operating Margin (TTM) | -1,685.01% |
| Diluted EPS (TTM) | -0.550 |
| Quarterly Revenue Growth (YOY) | 25.90% |
| Total Debt/Equity (MRQ) | 35.04% |
| Current Ratio (MRQ) | 3.53 |
| Operating Cash Flow (TTM) | -70.41 M |
| Levered Free Cash Flow (TTM) | -53.20 M |
| Return on Assets (TTM) | -44.04% |
| Return on Equity (TTM) | -278.55% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Precigen, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 4.0 |
| Average | 0.83 |
|
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 10.56% |
| % Held by Institutions | 67.08% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Patient Capital Management, Llc | 30 Jun 2026 | 19,036,976 |
| Diametric Capital, Lp | 30 Jun 2026 | 9,269,926 |
| Occam Crest Management Lp | 30 Jun 2026 | 3,605,941 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| THOMASIAN HARRY JR. | - | - | 0 | 0 |
| Aggregate Net Quantity | 0 | |||
| Aggregate Net Value ($) | 0 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| THOMASIAN HARRY JR. | Officer | 23 Sep 2026 | Option execute | 53,665 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |